References
- Vecchione A, Croce MC. Apoptomirs. Endocr Relat Cancer 2010;17:37–50.
- Stenvang J, Petri A, Lindow M, et al. Inhibition of microRNA function by antimir oligonucleotides. Silence 2012;3:1.
- Dejean LM, Ryu SH, Martinez-Caballero S, et al. MAC and Bcl-2 family proteins conspire in a deadly plot. Biochim Biophys Acta 2010;1797:1231–1238.
- Reilly JT. Pathogenic insight and prognostic information from standard and molecular cytogenetic studies in the BCR-ABL-negative myeloproliferative neoplasms (MPNs). Leukemia 2008;22: 1818–1827.
- Tognon R, Gasparotto EP, Leroy JM, et al. Differential expression of apoptosis-related genes from death receptor pathway in chronic myeloproliferative diseases. J Clin Pathol 2011;64:75–82.
- Tognon R, Gasparotto EP, Neves RP, et al. Deregulation of apoptosis-related genes is associated with PRV1 overexpression and JAK2 V617F allele burden in essential thrombocythemia and myelofibrosis. J Hematol Oncol 2012;5:2.
- Gasparotto EPL, Tognon R, Ferreira AF, et al. Deregulated expression of A1, Bcl-2, Bcl-xL, and Mcl-1 antiapoptotic proteins and Bid, Bad, and Bax proapoptotic genes in polycythemia vera patients. Braz J Pharm Sci 2011;47:873–86.
- Schoette D, Pieters R, Den Boer ML. MicroRNAs in acute leukemia: from biological players to clinical contributors. Leukemia 2012;26: 1–12.
- Calin GA, Cimino A, Fabbri M, et al. Mir-15a and miR16-1 cluster functions in human leukemia. Proc Natl Acad Sci USA 2008;105: 5166–5171.
- Rhyasen GW, Starczynowski DT. Deregulation of microRNA in myelodysplastic syndrome. Leukemia 2012;26:13–22.
- Bruchova H, Yoon D, Agarwal AM, et al. Erythropoiesis in polycythemia vera is hyper-proliferative and has accelerated maturation. Blood Cells Mol Dis 2009;43:81–87.
- Guglielmelli P, Tozzi L, Pancrazzi A, et al. MicroRNA expression profile in granulocytes from primary myelofibrosis patients. Exp Hematol 2007;35:1708–1718.
- Bortoluzzi S, Bisognin A, Biasiolo M, et al. Characterisation and discovery of novel miRNAs and moRNAs in JAK2 V617F mutated Set2 cells. Blood 2012;119:120–130.
- Selcuklu DS, Donoghue ATM, Spillane C. miR-21 as a key regulator of oncogenic processes. Biochem Soc Trans 2009;37:918–925.
- Jazbutyte V, Thum T. MicroRNA-21: from cancer to cardiovascular disease. Curr Drug Targets 2010;11:926–935.
- Li G, Miskimen KL, Wang Z, et al. STAT5 requires N-domain for suppression of miR15/16, induction of bcl-2, and survival signaling in myeloproliferative disease. Blood 2011;114:416–424.